Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
McKernan; Patricia A.
Address:
Woodinville, WA
No. of patents:
13
Patents:












Patent Number Title Of Patent Date Issued
7101907 Topical administration of statins for treatment of bone disorders September 5, 2006
The topical administration of statins for the treatment of bone disorders is disclosed.
6642216 Isoprenoid pathway inhibitors for stimulating bone growth November 4, 2003
Compounds of the formula ##STR1##wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula ##STR2## or a stereoisomer thereof, wherein R.sup.1 is substituted or unsubstituted alkyl
6395740 Calcitonin mimetics May 28, 2002
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6391917 Dialkyl ureas as calcitonin mimetics May 21, 2002
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6376476 Isoprenoid pathway inhibitors for stimulating bone growth April 23, 2002
Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-pl
6255351 Dialkyl ureas as calcitonin mimetics July 3, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6221913 Dialkyl ureas as calcitonin mimetics April 24, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6124299 Calcitonin mimetics September 26, 2000
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6080779 Compositions and methods for stimulating bone growth June 27, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may opti
6022887 Compositions and methods for stimulating bone growth February 8, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optio
5698521 Native calcitonin mimetics December 16, 1997
The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.
5677334 Method for inhibiting the stimulation of a glucagon-induced response pathway in a warm-blooded a October 14, 1997
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response
5508304 Glucagon antagonists and methods relating thereto April 16, 1996
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response










 
 
  Recently Added Patents
Selection of system parameters based on non-acoustic sensor information
Synergistic compositions for the treatment of topical viral infections
Single-pass Barankin Estimation of scatterer height from SAR data
Agglutination judgment method
Methods of enhancing diabetes resolution
Synchronization of web applications and media
Structural plasticity in spiking neural networks with symmetric dual of an electronic neuron
  Randomly Featured Patents
Artificial kidney with device for filtering dialysis liquid
Photosensitizers for targeted photodynamic therapy
Method and arrangement for controlling an internal combustion engine with a detecting device utilizing two sensors for generating signals which change in mutually opposite directions
Mobile machine with an electric traction motor of a traction drive, an electric pump motor of a hydraulic work system, and fluid cooling
Method and apparatus for providing multiple quality of service levels in a wireless packet data services connection
Turbomachine rotor assembly having reduced stress concentrations
Filtration process for separating particles from liquid coolants in lens grinding devices
Condensation injection molding process for producing bottle preforms of polyethylene terephthalate and/or its copolyesters and resultant preforms
Printed circuit board connector contact
Elevator door apparatus